Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, studies immunotherapy and immunopathology in cancer and infectious diseases. His current research interests include investigating and understanding the mechanisms underlying IR-induced extrinsic resistance as well as testing newly developed personalized immunotherapies to overcome these resistance mechanisms for improved and long-lasting tumor control.
After completing his clinical training in pathology at Washington University in St. Louis (1998), Dr. Fu organized his own team to focus his research on understanding the role of the lymphoid microenvironment in cellular and humoral immune responses using various TNF superfamily members such as the LIGHT/lymphotoxin pathway.
His team has published more than 50 papers relating to the mechanistic understanding of autoimmunity and immunity against pathogens and tumor in top journals (e.g., Science, Nature, Nature Immunology, Nature Medicine, Cancer Cell, Immunity, Journal of Experimental Medicine, and Journal of Clinical Investigation). He has directed clinical, translational, and preclinical studies in immunology––tumor immunology in particular––for more than 15 years. Recently, his team has been developing novel immunotherapeutic molecules, antibodies and armed antibodies by protein engineering. They have established mouse tumor models expressing various oncogenic receptors to mimic clinical tumors and have made significant progress in understanding how traditional cancer therapies both rely on and impact the immune system.
- Medical School
- Shanghai Medical University (1983), Medicine
- Graduate School
- University of Miami (1990), Immunology
- IR-mediated immunity and tumor regression
- Lymphotoxin biology and gut Immunity
- Next generation antibody-based molecules
- Tumor immunology
- Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
- Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX J. Clin. Invest. 2014 Feb 124 2 687-95
- Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
- Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX Cancer Cell 2014 Jan 25 1 37-48
- Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing.
- Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, Fu YX J. Immunol. 2013 Jun 190 11 5874-81
- Effective anti-neu initiated anti-tumor responses require the complex role of CD4+ T cells.
- Mortenson E, Park S, Zhujun J, Wang S, Fu YX Clin. Cancer Res. 2013 Jan
- Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.
- Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX Mol. Ther. 2013 Jan 21 1 91-100
- The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
- Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL Cancer Res. 2011 Apr 71 7 2488-96
- The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
- Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX Cancer Cell 2010 Aug 18 2 160-70
- Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition.
- Wang Y, Zhu M, Yu P, Fu YX J. Immunol. 2010 Feb 184 3 1589-95
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.
- Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX Blood 2009 Jul 114 3 589-95
- Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
- Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX J. Immunol. 2007 Aug 179 3 1960-8